Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Breakthroughs in Epidermolysis Bullosa: From Supportive Care to Precision Therapies
Description
The speaker introduces a session on epidermolysis bullosa (EB), describing it as a historically devastating disease marked by fragile skin, chronic wounds, pain, and intensive supportive care focused on infection prevention, wound management, and stabilization rather than altering the disease itself. She emphasizes that EB care is now entering a new era of precision medicine, with deeper understanding of skin biology, inflammatory pathways, and genotype-phenotype relationships, alongside FDA-approved and gene-based therapies that are moving from theory to clinical reality. The discussion frames EB care as progressing from survival and optimization toward intervention, including ex vivo gene-corrected grafts, in vivo gene delivery, and targeted anti-inflammatory treatments. The central challenge is no longer only scientific discovery but implementation: identifying appropriate candidates, deciding when to escalate therapy, delivering treatments in practice, supporting families through uncertainty, and preserving humanity, access, and equity. The message highlights that EB affects daily life in homes as well as clinics, and that the responsibility is now to translate breakthroughs into everyday dermatologic care.
View moreConclusions
- Epidermolysis bullosa care is shifting from stabilization and palliation toward precision correction of the underlying disease biology.
- FDA-approved and gene-based therapies are now making molecular intervention in EB a clinical reality rather than a theoretical future.
- The field has progressed through three stages—survival, optimization, and now molecular intervention—changing the goals of care.
- Successful EB breakthroughs must be deliverable in real-world practice and reach patients to matter.
- Clinical decision-making now centers on selecting the right candidates, timing escalation appropriately, and building the infrastructure to support treatment.
- EB is no longer viewed as only a structural skin disorder, but also as a condition involving molecular correction, immune modulation, and systems of care.
- Despite scientific advances, preserving humanity, family support, access, and equity remains essential in EB care.
- The overall message is that inaction is no longer acceptable because effective intervention is becoming possible.